FT573

B7H3 belongs to the B7 family of immune checkpoint inhibitors and is expressed on a wide range of solid and hematologic malignancies. B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients.

We are developing FT573, an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master engineered iPSC line. FT573 incorporates four functional modifications: a proprietary CAR that targets B7H3; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor that augments ADCC; an IL-15 receptor fusion (IL-15RF) that promotes enhanced NK cell activity; and the elimination of CD38 expression which enhances NK cell metabolic fitness, persistence and anti-tumor functionality.